[18F]mFBG PET/CT imaging outperforms MRI and [68 Ga]Ga-DOTA-TOC PET/CT in identifying recurrence pheochromocytoma

18F-MFBG PET/CT and MRI in Identifying Brain Metastases in a Posttreatment Neuroblastoma Patient

“…Currently, 123 I-MIBG SPECT/CT is the most common nuclear medicine imaging modality in the evaluation of patients with neuroblastoma with reasonable accuracy, 1-4 whereas 18 F-MFBG PET/CT had only recently been proposed as a potential alternative in the evaluation of different neural crest tumors. [5][6][7] In patients with metastatic pheochromocytomas and paragangliomas, MFBG PET/CT offers a similar or slightly better accuracy than DOTATATE PET/CT. 8 Recent publications have shown that 18 F-MFBG PET/CT has significant advantage over conventional 123 I-MIBG SPECT/CT in the evaluation of neuroblastoma.…”

“…New findings in the left cerebellopontine angle and internal auditory canal showed equal T1 ( D ) and T2 ( E ) signals with abnormal enhancement ( F ), corresponding to the sites of increased MFBG activity on prior PET/CT study. Currently, 123 I-MIBG SPECT/CT is the most common nuclear medicine imaging modality in the evaluation of patients with neuroblastoma with reasonable accuracy, 1–4 whereas 18 F-MFBG PET/CT had only recently been proposed as a potential alternative in the evaluation of different neural crest tumors 5–7 . In patients with metastatic pheochromocytomas and paragangliomas, MFBG PET/CT offers a similar or slightly better accuracy than DOTATATE PET/CT 8 .…”